Table 4.
Comparison of crude mean EORTC scores of all patients and survivors who completed the same questionnaire during and within 2 years before COVID-19 (n = 1022).
| Crude mean EORTC scoresa | Before COVID-19b | During COVID-19 | Mean difference (95% CI) | P c |
|---|---|---|---|---|
| EORTC-QLQ30 and BR23, mean (SD) | ||||
| Quality of life (QoL) | 76.3 (18.2) | 78.9 (16.6) | 2.6 (-3.6 to -1.6) | <.001 |
| Future perspectives (FP) | 70.8 (24.9) | 69.7 (20.0) | −1.1 (-0.2 to 2.4) | .09 |
| Functioning scales | ||||
| Physical functioning (PF) | 87.0 (15.1) | 88.6 (14.0) | 1.5d (-2.2 to -0.9) | <.001 |
| Role functioning (RF) | 78.3 (26.3) | 81.8 (23.6) | 3.5 (-5.1 to -1.9) | <.001 |
| Emotional functioning (EF) | 82.6 (18.7) | 77.9 (17.3) | −4.6 (3.6 to 5.6) | <.001 |
| Social functioning (SF) | 86.8 (20.8) | 88.5 (20.2) | 1.6d (-2.9 to -0.4) | .01 |
| Cognitive functioning (CF) | 80.8 (20.9) | 82.2 (18.3) | 1.4 (-2.4 to -0.4) | .004 |
| Symptom scales | ||||
| Dyspnea (D) | 12.0 (21.6) | 10.5 (18.6) | −1.5 (0.3 to 2.7) | .01 |
| Insomnia (I) | 27.3 (28.3) | 27.1 (26.5) | −0.2 (-1.5 to 1.8) | .85 |
| Financial difficulties (FD) | 6.2 (16.6) | 5.9 (16.0) | −0.3 (-0.6 to 1.2) | .57 |
EORTC QLQ-C30/BR23 scores range from 0 to 100. Higher scores represent better outcomes for QoL, FP, and functioning scales, and lower scores on symptom scales indicate better outcomes. CI = Confidence Interval; COVID-19 = coronavirus disease 2019; EORTC QLQ-C30/BR23= European Organization for Research and Treatment of Cancer core and breast cancer-specific Quality of Life Questionnaire.
Last valid score measured within the last 2 years before the start of the COVID-19 pandemic.
Crude mean EORTC scores were compared with a 2-sided paired samples t test.
Mean difference differs from difference between mean scores because of rounding.